Lymphoma Therapy
Novel assays facilitate rituximab monitoring
Published in Medical Devices and Surgical Technology Week, October 17th, 2004
RTX is "a monoclonal antibody which targets CD20 and is approved for treatment of non-Hodgkin's lymphoma (NHL), with an approximate 50% overall response rate among NHL patients," according to scientists in the United States. "Accurate determination of RTX concentrations in patient plasmas is important for proper dosing of patients and for correlating RTX concentrations with clinical responses."
However, there is "currently no assay available for RTX which utilizes easily obtainable commercial reagents," noted P.V. Beum and colleagues at the University of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices and Surgical Technology Week
More Articles from Medical Devices and Surgical Technology Week
- Cancer Therapy
Liposomal IUdR is an effective radiosensitizer with low toxicity - Drug Delivery
Novel method devised for assessment of drug solubility in polymeric matrices - Knee Replacement
CT navigation associated with improved UKR outcome - Medical Devices
Focused ultrasound can induce apoptosis signals in lymphoblasts - Abdominal Aortic Aneurysm
Changes in abdominal aortic aneurysm morphology occur after endovascular repair - Alzheimer Disease
License obtained for brain monitoring technology - More from this issue of Medical Devices and Surgical Technology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
